$280 Million is the total value of Fairmount Funds Management LLC's 18 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 27.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
INSM | Sell | INSMED INC | $32,018,000 | -5.7% | 961,797 | -9.0% | 11.45% | -20.4% |
FOLD | Sell | AMICUS THERAPEUTICS INC | $30,372,000 | +47.8% | 1,315,395 | -9.6% | 10.86% | +24.8% |
IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $26,257,000 | +33.6% | 565,890 | -5.2% | 9.39% | +12.8% |
ACAD | Sell | ACADIA PHARMACEUTICALS INC | $24,074,000 | -9.9% | 450,317 | -30.5% | 8.61% | -23.9% |
Sell | TRILLIUM THERAPEUTICS INC | $21,744,000 | -1.8% | 1,478,181 | -5.1% | 7.78% | -17.1% | |
ALLK | Sell | ALLAKOS INC | $20,673,000 | +54.1% | 147,662 | -10.3% | 7.39% | +30.2% |
ZGNX | Sell | ZOGENIX INC | $19,603,000 | +3.4% | 980,645 | -7.2% | 7.01% | -12.6% |
ENTA | Sell | ENANTA PHARMACEUTICALS INC | $6,333,000 | -14.7% | 150,433 | -7.3% | 2.26% | -28.0% |
KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -212,746 | -100.0% | -1.38% | – |
NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -372,748 | -100.0% | -1.90% | – |
UMRX | Exit | UNUM THERAPEUTICS INC | $0 | – | -6,235,903 | -100.0% | -5.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ARGENX SE | 16 | Q3 2023 | 9.3% |
AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
INSMED INC | 12 | Q3 2022 | 15.0% |
ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
ALLAKOS INC | 12 | Q3 2022 | 7.4% |
AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-25 |
SC 13D/A | 2024-04-25 |
4 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-04-01 |
4 | 2024-04-01 |
SC 13D/A | 2024-04-01 |
SC 13D/A | 2024-04-01 |
SC 13D/A | 2024-04-01 |
SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.